Pricing Log in Create free account
Friday 6 November 2026 Export KIDS’s income statement to Excel — free account

OrthoPediatrics Corp.

KIDS Healthcare Medical Devices

OrthoPediatrics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $236.3 million, up 15.4% from fiscal 2024.

Revenue
+18.6%
EPS
+50.9%
Free cash flow
+146.6%
Total debt
+0.99%

Quarter to September 2026, against a year earlier

31.56 0.66 −2.05%
Market cap
$841.3M
P/E
0.0×
Fwd P/E
−25.5×
Dividend yield
—
F-score
4/9
Altman Z
1.49
Beneish M
−2.67
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 47.75
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 5 — — — — 6 6 — —
Insider Ownership 24.65%

Capital & Financial Ratios $m

Size
Market Cap 841.28
Revenue ttm 264.14
Net income ttm (33.88)
Free cash flow ttm 3.18
Net debt Q 52.91
Valuation
P/E 0.00
Forward P/E (25.50) (negative: loss-making)
Price / sales 2.94
Forward P/S Powerpack
Price / FCF 722.82
Price / book 2.29
Financial health
Current ratio Q 4.55 (at or above 1.5: strong)
Debt / equity Q 0.29 (at or below 0.5: strong)
Interest coverage Q (1.61)
Growth
Revenue growth Q +18.63% (above 0%: growing)
Operating income growth Q +55.19% (above 0%: growing)
EPS, this year +28.74% (at or above 15%: strong)
EPS, next year A +34.16% (at or above 15%: strong)
Revenue, next year A +14.92% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +40.17% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.1×, against a ten-year median of 6.8×; over the ten years it ranged from 1.0× in 2018 to 14.4× in 2021.
P/S against its own 10 years 26.02%
10-year low 10-year high
P/B against its own 10 years 40.65%
10-year low 10-year high
EV/Sales against its own 10 years 27.25%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 82 71 63 45
Receivables 35 42 54 60
Inventory 106 117 134 142
Other — — — —
226 237 256 253
2023 2024 2025 Q'26
Payables 13 9 19 24
ST’ Debt 0 0 0 0
Other 18 11 14 14
42 34 46 56

Compound Annual Growth %

10y 5y 3y
Sales 22.52% 27.16% 24.56%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 8.10% (2.91%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.25 Actual −0.23

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.37 −0.26 Beat by 0.11
Q1 FY26 −0.38 −0.42 Miss by 0.04
Q2 FY26 −0.31 −0.26 Beat by 0.05
Q3 FY26 −0.25 −0.23 Beat by 0.02
Q4 FY26 −0.16 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.45) (0.30) (0.25) — —
’25 (0.46) (0.30) (0.50) (0.43) (1.69)
’24 (0.34) (0.26) (0.34) (0.69) (1.64)
’23 (0.30) (0.13) (0.20) (0.29) (0.92)
’22 (0.47) (0.02) 0.87 (0.35) 0.06
’21 (0.54) (0.19) (0.11) 0.00 (0.84)
’20 (0.30) (0.54) (0.24) (0.73) (1.82)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 59 71 73 — —
’25 52 61 61 62 236
’24 45 53 55 53 205
’23 32 40 40 38 149
’22 23 33 35 31 122
’21 21 27 25 25 98
’20 16 14 22 19 71
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 1 5 — —
’25 (4) (10) (1) 10 (5)
’24 (7) (6) (10) (4) (27)
’23 (6) (4) (9) (8) (27)
’22 (4) (8) (6) (3) (22)
’21 (2) (9) (1) (1) (13)
’20 (7) (8) (4) 0 (19)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (3) 2 — —
’25 (8) (14) (3) 10 (16)
’24 (13) (13) (12) (4) (41)
’23 (11) (10) (11) (13) (46)
’22 (8) (13) (7) (3) (32)
’21 (8) (11) (8) (3) (29)
’20 (11) (10) (5) (4) (30)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 37 46 58 73 71 98 122 149 205 236 264 +22.8% 272 305 340 +12.9%
Gross margin, % 70.69 75.52 74.15 75.28 77.42 74.86 74.14 74.80 72.58 73.05 73.76 +2.4 pt
EBT (7) (9) (12) (13) (34) (17) (4) (21) (42) (39) (34) +21.9%
EBT margin, % (17.62) (19.58) (20.89) (17.48) (47.37) (17.73) (3.02) (14.33) (20.48) (16.58) (12.72) +1.0 pt
Net income (7) (9) (12) (14) (33) (16) 1 (21) (38) (40) (34) +22.1%
Per share, $
Per share, $ Revenue 21.39 11.36 4.58 4.96 3.94 5.09 5.91 6.56 8.87 10.07 10.94 (8.0%)
Earnings (7.14) (6.12) (0.96) (0.94) (1.82) (0.84) 0.06 (0.92) (1.64) (1.69) (1.43) (14.8%)
Cash flow (0.64) (1.80) (1.24) (1.22) (1.03) (0.68) (1.05) (1.19) (1.17) (0.21) 0.52 (11.8%)
Capex (2.73) (1.63) (0.43) (0.83) (0.63) (0.83) (0.48) (0.84) (0.62) (0.47) (0.39) (17.7%)
Free cash flow (3.37) (3.43) (1.67) (2.04) (1.65) (1.51) (1.54) (2.03) (1.79) (0.68) 0.13 (16.3%)
Book value 3.44 11.82 6.50 9.73 13.00 11.70 18.29 16.63 15.36 14.77 14.05 +17.6%
Shares, m 2 4 13 15 18 19 21 23 23 23 24 +33.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 1,024.25 0.00 0.00 0.00 0.00 102.4
P/S 0.77 1.91 7.62 9.47 10.48 11.76 6.94 5.03 2.61 1.76 2.94 5.8
P/B 0.00 1.84 5.36 4.83 3.17 5.12 2.24 1.99 1.51 1.20 2.29 2.7
EV/Sales 1.35 1.54 6.93 8.84 9.30 11.21 5.96 4.55 2.62 1.91 3.14 5.4
EV/FCF (5.95) (5.10) (18.95) (21.48) (22.15) (37.82) (19.80) (14.69) (12.36) (24.95) 772.08 (18.3)
Cash, $m
Cash, $m Operating cash flow (1) (7) (16) (18) (19) (13) (22) (27) (27) (5) 12 +17.7%
Capex (5) (7) (5) (12) (11) (16) (10) (19) (14) (11) (9) +9.9%
Free cash flow (6) (14) (21) (30) (30) (29) (32) (46) (41) (16) 3 +11.7%
Balance, $m
Balance, $m Working capital 14 60 88 114 123 104 196 185 203 210 198 +35.6%
Net debt 16 (17) (39) (46) (84) (54) (119) (72) 2 34 53 +8.9%
Shareholders’ equity 6 47 82 142 235 225 379 377 355 347 339 +57.0%
Returns, %
Returns, % ROA (81.16) (41.65) (12.37) (9.33) (13.11) (5.21) 0.34 (4.84) (8.29) (8.08) (6.76) +73.1 pt
ROIC (17.47) (13.32) (14.11) (5.88) (11.10) (6.57) (6.11) (5.49) (6.14) (6.44) (3.95) +11.0 pt
ROE 139.76 264.17 (18.61) (12.25) (17.47) (7.07) 0.41 (5.55) (10.34) (11.31) (9.84) (151.1) pt
People
People Employees 62 69 80 94 116 133 203 247 562 602 — +28.7%
Revenue/emp, $m 0.60 0.66 0.72 0.77 0.61 0.74 0.60 0.60 0.36 0.39 — (4.6%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

OrthoPediatrics Corp. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AHCO AdaptHealth Corp. $1.0B — (loss-making) — (loss-making) +10.90% (above 0%: growing) n/m −23.58% (below 0%: shrinking) 15.40% (20.91%) Compare
BVS Bioventus Inc. $899.9M 12.3× 17.2× +2.73% (above 0%: growing) +100.60% (above 0%: growing) −31.40% (below 0%: shrinking) 68.19% 6.81% Compare
QDEL QuidelOrtho Corporation $880.5M — (loss-making) — (loss-making) −11.57% (below 0%: shrinking) n/m +120.70% (above 0%: growing) 46.79% (1.21%) Compare
BBNX Beta Bionics, Inc. $842.1M — (loss-making) — (loss-making) +30.28% (above 0%: growing) n/m −45.46% (below 0%: shrinking) 57.26% (74.94%) Compare
KIDS OrthoPediatrics Corp. $841.3M — (loss-making) — (loss-making) +18.63% (above 0%: growing) n/m +146.64% (above 0%: growing) 74.28% (5.81%)
VREX VAREX IMAGING $783.0M 34.8× 39.2× +3.69% (above 0%: growing) n/m +757.14% (above 0%: growing) 36.44% 10.83% Compare
INMD InMode Ltd. $771.1M 10.7× 11.8× −0.01% (below 0%: shrinking) −30.95% (below 0%: shrinking) −12.63% (below 0%: shrinking) 74.82% 12.82% Compare
PACB Pacific Biosciences of California, Inc. $755.3M — (loss-making) — (loss-making) +5.52% (above 0%: growing) n/m −101.95% (below 0%: shrinking) 33.21% (91.22%) Compare
CTKB Cytek Biosciences, Inc. $701.9M — (loss-making) — (loss-making) +1.79% (above 0%: growing) n/m −30.25% (below 0%: shrinking) 58.63% (15.82%) Compare
Median of peers $812.6M 12.3× 17.2× +3.21% — −26.91% 52.03% (8.51%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 20 April 2026

Ownership

Directors and executive officers, together 32.50%
David R. Pelizzon 27.00%
Squadron Capital LLC 26.90%
Brown Advisory Incorporated 6.30%
Integrated Core Strategies (US) LLC 5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

OrthoPediatrics Corp. (KIDS) Latest News

28 Oct

Impact 4 · · Moby earnings
Impact 3 · · Associated Press

27 Oct

Impact 4 · · The Motley Fool
Impact 4 · · MarketBeat transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire earnings
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

7 Oct

Impact 4 · · GlobeNewswire

22 Sep

Impact 4 · · GlobeNewswire

11 Sep

Impact 3 ·

25 Aug

Impact 4 ·

14 Aug

Impact 4 · · MarketBeat

11 Aug

Impact 3 · · The Motley Fool transcript

5 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript

4 Aug

Impact 4 ·
Impact 3 · · MarketBeat
Impact 3 ·

24 Jun

Impact 3 · · GlobeNewswire

25 May

Impact 3 · · Simply Wall St.

1 May

Impact 4 · · GuruFocus.com

30 Apr

Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 3 · · Moby
Impact 3 · · MarketBeat
Impact 3 · · Zacks
Impact 3 · · Zacks

16 Apr

Impact 4 · · MarketBeat
stockrow.com/KIDS · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com